GlaxoSmithKline Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on GlaxoSmithKline Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how GlaxoSmithKline Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with GlaxoSmithKline Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
GlaxoSmithKline Pharmaceuticals Ltd (GSK India), a subsidiary of GlaxoSmithKline Plc, is a biopharmaceutical company. The company's primary activities involve the development and marketing of vaccines and medicines, with a focus on infectious diseases, human immunodeficiency viruses (HIV), oncology and immunology. GSK India's product portfolio includes a wide range of general medicines such as minerals, vitamins, hormones, nutritionals, anti-infectives, dermatological, pain management, and respiratory drugs, as well as vaccines for children and adults. These products serve a variety of patient needs, from managing fever and pain to treating skin conditions, respiratory issues, and hypothyroidism. The company markets its products under various brand names such as havrix, infanrix ,hexa, synflorix, varilrix, fluarix tetra, menveo, augmentin, ceftum, calpol, nucala, trelegy, seretide, t-bact, neosporin, physiogel, tenovate, flutivate, cobadexczs, ccm, eltroxin, betnovate-n. The company operates through a network of contract manufacturing organizations (CMOs) across India. GSK India is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
GSK House, Dr. Annie Besant Road, Worli, Mumbai, Maharashtra, 400030
Website
india-pharma.gsk.com/en-in
Telephone
91 22 24959595
No of Employees
3,113
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLAXO (NSE)
Revenue (2025)
$438.6M
1.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
11.7%
(2025 vs 2024)
Market Cap*
$4.4B
Net Profit Margin (2025)
XYZ
9.6%
(2025 vs 2024)
* As of and is in US$
GlaxoSmithKline Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| General Medicines | Shingrix |
| Vaccines for Adults and Children | Boostrix |
| Specialty Medicines | Cervarix |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In August, the company introduced two precision therapies, Jemperli (dostarlimab) and Zejula (niraparib), in India. |
| 2023 | New Product Approvals | In April, the company launched Shingrix in India, a vaccine for the prevention of shingles in adults aged 50 years and above. |
| 2022 | New Products/Services | In April, the company has launched Trelegy Ellipta single-inhaler triple therapy (SITT) used for the treatment of Chronic Obstructive Pulmonary Disease (COPD). |
Competitor Comparison
| Key Parameters | GlaxoSmithKline Pharmaceuticals Ltd | Dr. Reddy's Laboratories Ltd | Aurobindo Pharma Ltd | Morepen Laboratories Ltd | Bliss GVS Pharma Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Hyderabad | Hyderabad | Gurugram | Mumbai |
| State/Province | Maharashtra | Telangana | Telangana | Haryana | Maharashtra |
| No. of Employees | 3,113 | 26,944 | 9,107 | 1,814 | 966 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Renu Sud Karnad | Chairperson | Executive Board | - | 67 |
| Ronojit Biswas | Chief Financial Officer | Senior Management | 2026 | - |
| Bhushan Akshikar | Managing Director | Executive Board | 2022 | - |
| Dr. Shalini Menon | Head - Medical Affairs | Senior Management | - | - |
| Vibhuti Gupta | Vice President - Commercial Operations and Strategy | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer